Thursday, May 4, 2006

lisofylline and exendin-4 by Yang at University of Virginia

in this study we combined lisofylline to suppress autoimmunity and exendin-4 to enhance β-cell proliferation for treating autoimmune-mediated diabetes in the non-obese diabetic (NOD) mouse model. We found that this combined therapy effectively reversed new-onset diabetes within a week of therapy, and even maintained euglycemia up to 145 days after treatment withdrawal. 


  1. I don't know whether you caught the Feb 29, 2012 news release, but Islet Sciences, Inc. announced that the company entered into a Share Exchange Agreement to acquire DiaKine Therapeutics, Inc., whose most most clinically advanced drug is/was Lisofylline. The full press release can be viewed at in case you're interested.


  2. Thanks for sharing this type of blog. I really liked it. This information is useful as well as informative the way this blog describe is amazing. Keep it up. Good job. Visit here :